传染性软疣的治疗:VP-102的III期CAMP试验取得阳性结果

2020-01-20 Allan MedSci原创

Verrica Pharmaceuticals是一家开发皮肤病药物的制药公司,今天公布了关键性III期CAMP试验的最新数据,该试验旨在评估VP-102(斑蝥素局部用溶液)治疗软疣的安全性和有效性。

Verrica Pharmaceuticals是一家开发皮肤病药物的制药公司,今天公布了关键性IIICAMP试验的最新数据,该试验旨在评估VP-102(斑蝥素局部用溶液)治疗软疣的安全性和有效性。分析表明,在所有部位,VP-102组中所有病变均被完全清除的患者百分比在统计学上显著高于对照组。

意向性治疗(ITT)患者群体在基线时的特定区域有软疣病变,包括:头/颈部(n = 77 VP-102n = 53 对照组);胸部/腹部(n = 142118);后背/臀部(n = 11791);腹股沟(n = 2825);上肢(n = 179131)和下肢(n = 186141)。通过评估每个位置完全清除病变的受试者百分比来衡量疗效。数据表明,在研究结束时(第84天),与对照组相比,接受VP-102治疗的患者在所有身体部位的病变清除率具有统计学上显著更高的百分比。


原始出处:

https://www.firstwordpharma.com/node/1694577

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-06-25 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-11-26 爆笑小医
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-04-29 whmdzju
  7. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97514, encryptionId=679b9e514c8, topicName=阳性结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28fb22837833, createdName=12498cb5m20暂无昵称, createdTime=Sun Nov 08 20:43:00 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911507, encodeId=e9ff191150e2c, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Jun 25 06:43:00 CST 2020, time=2020-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916226, encodeId=ff911916226c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Nov 26 18:43:00 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665359, encodeId=f74f166535991, content=<a href='/topic/show?id=9ff91852290' target=_blank style='color:#2F92EE;'>#VP-102#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18522, encryptionId=9ff91852290, topicName=VP-102)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cc25947045, createdName=12498e8em80暂无昵称, createdTime=Fri May 01 09:43:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738431, encodeId=c9df1e384312a, content=<a href='/topic/show?id=3eaf40057e' target=_blank style='color:#2F92EE;'>#cAMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4005, encryptionId=3eaf40057e, topicName=cAMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e334449341, createdName=1249883fm23暂无昵称, createdTime=Fri Nov 06 23:43:00 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675354, encodeId=61b816e535478, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Wed Apr 29 14:43:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602896, encodeId=d8aa1602896af, content=<a href='/topic/show?id=3a61400e5a' target=_blank style='color:#2F92EE;'>#CAMP试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4007, encryptionId=3a61400e5a, topicName=CAMP试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=505818973154, createdName=limedical1980, createdTime=Tue Jan 21 23:43:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]

相关资讯

斑蝥素治疗常见疣的II期临床研究取得积极成绩

Verrica是一家皮肤病学医疗公司,致力于为皮肤病患者提供先进疗法,近日公布了其II期临床研究COVE-1的正面结果,以评估VP-102治疗常见疣的临床有效性。

Verrica制药宣布FDA批准VP-102的新药申请,用于治疗感染性软疣

医学皮肤病学公司Verrica近日宣布,FDA已经批准了VP-102的新药申请,用以治疗传染性软疣。Verrica总裁兼首席执行官Ted White表示:“目前,目前尚无FDA批准的治疗方法,如患者未经治疗,感染性软疣很容易传播,病变平均持续13个月”。

2019年美国皮肤病学会(AAD)年会:Verrica制药公布了VP-102的全新临床试验结果

Verrica是一皮肤病学家医疗公司,致力于开发和商业化新型治疗方法,为皮肤病患者提供有意义的治疗手段,Verrica宣布将在2019年美国皮肤病学会(AAD)年会上公布两项III期临床试验结果,以证明候选化合物VP-102治疗传染性软疣患者的有效性和安全性。